Cyclacel Pharmaceuticals (BGMS) Competitors

Cyclacel Pharmaceuticals logo
$0.61 +0.04 (+6.28%)
Closing price 03:59 PM Eastern
Extended Trading
$0.65 +0.04 (+7.06%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BGMS vs. TLIH, CLWT, INEO, MWG, and SOS

Should you buy Cyclacel Pharmaceuticals stock or one of its competitors? Cyclacel Pharmaceuticals's main competitors and comparable companies include Ten-League International (TLIH), Euro Tech (CLWT), INNEOVA (INEO), Multi Ways (MWG), and SOS (SOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does Cyclacel Pharmaceuticals compare to Ten-League International?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Ten-League International (NASDAQ:TLIH) are both small-cap industrials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ten-League International has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -74.40%. Ten-League International's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals-74.40% -24.24% -21.39%
Ten-League International N/A N/A N/A

Cyclacel Pharmaceuticals has a beta of -0.44, suggesting that its share price is 144% less volatile than the broader market. Comparatively, Ten-League International has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Ten-League International. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for Ten-League International. Ten-League International's average media sentiment score of 0.00 beat Cyclacel Pharmaceuticals' score of -0.50 indicating that Ten-League International is being referred to more favorably in the news media.

Company Overall Sentiment
Cyclacel Pharmaceuticals Negative
Ten-League International Neutral

Ten-League International has higher revenue and earnings than Cyclacel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$1.86M2.17-$3M-$2.40N/A
Ten-League International$59.24M0.27$4.34MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ten-League International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Ten-League International beats Cyclacel Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Euro Tech?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Euro Tech (NASDAQ:CLWT) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Euro Tech
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cyclacel Pharmaceuticals has a beta of -0.44, indicating that its share price is 144% less volatile than the broader market. Comparatively, Euro Tech has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Euro Tech has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -74.40%. Euro Tech's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals-74.40% -24.24% -21.39%
Euro Tech N/A N/A N/A

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Euro Tech. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for Euro Tech. Euro Tech's average media sentiment score of 0.00 beat Cyclacel Pharmaceuticals' score of -0.50 indicating that Euro Tech is being referred to more favorably in the news media.

Company Overall Sentiment
Cyclacel Pharmaceuticals Negative
Euro Tech Neutral

Euro Tech has higher revenue and earnings than Cyclacel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$1.86M2.17-$3M-$2.40N/A
Euro Tech$13.27M0.63$160KN/AN/A

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 2.9% of Euro Tech shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 79.0% of Euro Tech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Euro Tech beats Cyclacel Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to INNEOVA?

INNEOVA (NASDAQ:INEO) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than INNEOVA. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 1 mentions for INNEOVA. INNEOVA's average media sentiment score of 0.00 beat Cyclacel Pharmaceuticals' score of -0.50 indicating that INNEOVA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
INNEOVA
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cyclacel Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

INNEOVA has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.44, meaning that its stock price is 144% less volatile than the broader market.

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

INNEOVA has higher revenue and earnings than Cyclacel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INNEOVA$58.42M0.11-$400KN/AN/A
Cyclacel Pharmaceuticals$1.86M2.17-$3M-$2.40N/A

INNEOVA has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -74.40%. INNEOVA's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
INNEOVAN/A N/A N/A
Cyclacel Pharmaceuticals -74.40%-24.24%-21.39%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INNEOVA
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

INNEOVA beats Cyclacel Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Multi Ways?

Multi Ways (NYSE:MWG) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Multi Ways
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Multi Ways. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 1 mentions for Multi Ways. Cyclacel Pharmaceuticals' average media sentiment score of -0.50 beat Multi Ways' score of -0.91 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Multi Ways
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
Cyclacel Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

0.8% of Multi Ways shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Multi Ways has higher revenue and earnings than Cyclacel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Multi Ways$44.77M0.13$1.79MN/AN/A
Cyclacel Pharmaceuticals$1.86M2.17-$3M-$2.40N/A

Multi Ways has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.44, indicating that its share price is 144% less volatile than the broader market.

Multi Ways has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -74.40%. Multi Ways' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Multi WaysN/A N/A N/A
Cyclacel Pharmaceuticals -74.40%-24.24%-21.39%

Summary

Multi Ways and Cyclacel Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to SOS?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and SOS (NYSE:SOS) are both small-cap industrials companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Cyclacel Pharmaceuticals has a beta of -0.44, suggesting that its stock price is 144% less volatile than the broader market. Comparatively, SOS has a beta of 2.72, suggesting that its stock price is 172% more volatile than the broader market.

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 1.9% of SOS shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of SOS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SOS has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -74.40%. SOS's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals-74.40% -24.24% -21.39%
SOS N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
SOS
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than SOS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$1.86M2.17-$3M-$2.40N/A
SOS$113.52M0.03-$97.32MN/AN/A

In the previous week, Cyclacel Pharmaceuticals and Cyclacel Pharmaceuticals both had 2 articles in the media. SOS's average media sentiment score of 0.00 beat Cyclacel Pharmaceuticals' score of -0.50 indicating that SOS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cyclacel Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
SOS
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

SOS beats Cyclacel Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGMS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGMS vs. The Competition

MetricCyclacel PharmaceuticalsTrading Companies & Distributors IndustryIndustrials SectorNASDAQ Exchange
Market Cap$3.81M$9.56B$9.83B$11.70B
Dividend YieldN/A3.53%2.95%4.65%
P/E RatioN/A36.5729.9326.67
Price / Sales5.391.422.915.53
Price / CashN/A28.0019.7221.66
Price / Book0.603.103.633.65
Net Income-$3M$374.26M$612.75M$394.00M
7 Day Performance-13.97%-3.86%-4.27%-6.39%
1 Month Performance-34.52%-4.38%-4.19%-8.77%
1 Year Performance-52.64%9.18%0.73%-8.47%

Cyclacel Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGMS
Cyclacel Pharmaceuticals
0.9417 of 5 stars
$0.61
+6.3%
N/AN/A$3.81M$750KN/A12
TLIH
Ten-League International
N/A$5.85
-0.7%
N/A+38.8%$17.20M$59.24MN/A70
CLWT
Euro Tech
1.1139 of 5 stars
$1.15
-5.0%
N/A-0.5%$9.01M$13.27MN/A47
INEO
INNEOVA
0.3679 of 5 stars
$0.54
-8.1%
N/A-27.7%$7.20M$58.42MN/AN/A
MWG
Multi Ways
N/A$1.39
-4.5%
N/A-43.5%$7.11M$44.77MN/A92

Related Companies and Tools


This page (NASDAQ:BGMS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners